Mitochondrial complex I deficiency: Clinical Trials

2 trials for Mitochondrial complex I deficiency, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Completed 1

Follow Mitochondrial complex I deficiency: new trials by email Literature Review of Mitochondrial complex I deficiency trials Research Report on Mitochondrial complex I deficiency

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Elamipretide, Placebo - Mitochondrial Myopathies, Mitochondrial Pathology
Phase 3CompletedStealth BioTherapeutics Inc.1022022-04-292025-10-24
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Mitochondrial Disorders, Mitochondrial Genetic Disorders
RecruitingColumbia University10002011-01-312026-02-04

Narrower conditions

Mitochondrial Diseases (2)  ·  Mitochondrial Myopathies (2)  ·  Ophthalmoplegia, Chronic Progressive External (2)  ·  Acidosis, Lactic (1)  ·  Barth Syndrome (1)  ·  Brain Diseases (1)  ·  Cytochrome-c Oxidase Deficiency (1)  ·  Deafness (1)  ·  Diabetes Mellitus (1)  ·  Kearns-Sayre Syndrome (1)  ·  Leigh Disease (1)  ·  Leukoencephalopathies (1)  ·  MELAS Syndrome (1)  ·  MERRF Syndrome (1)

Broader conditions

Chronic Disease (2)  ·  Cranial Nerve Diseases (2)  ·  Disease Attributes (2)  ·  Eye Diseases (2)  ·  Metabolic Diseases (2)  ·  Muscular Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Neuromuscular Diseases (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Ocular Motility Disorders (2)  ·  Ophthalmoplegia (2)  ·  Paralysis (2)  ·  Pathologic Processes (2)

Interventions

arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)

Sponsors

Columbia University (1)  ·  Stealth BioTherapeutics Inc. (1)

Countries

United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Michio Hirano, MD (1)

NIH funding

U54NS078059 (1)